Trexquant Investment LP Makes New $6.50 Million Investment in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Trexquant Investment LP acquired a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 135,873 shares of the biopharmaceutical company's stock, valued at approximately $6,496,000. Trexquant Investment LP owned about 0.11% of Halozyme Therapeutics at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of the business. Vanguard Group Inc. raised its position in Halozyme Therapeutics by 3.0% during the 4th quarter. Vanguard Group Inc. now owns 13,281,714 shares of the biopharmaceutical company's stock worth $634,999,000 after purchasing an additional 386,618 shares during the last quarter. Geode Capital Management LLC increased its stake in Halozyme Therapeutics by 1.0% in the third quarter. Geode Capital Management LLC now owns 3,060,131 shares of the biopharmaceutical company's stock valued at $175,194,000 after purchasing an additional 30,901 shares in the last quarter. Charles Schwab Investment Management Inc. raised its stake in Halozyme Therapeutics by 0.6% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,783,177 shares of the biopharmaceutical company's stock worth $85,254,000 after buying an additional 9,780 shares during the period. Norges Bank bought a new position in shares of Halozyme Therapeutics in the 4th quarter worth $60,054,000. Finally, Arrowstreet Capital Limited Partnership grew its holdings in shares of Halozyme Therapeutics by 141.3% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 992,887 shares of the biopharmaceutical company's stock valued at $47,470,000 after buying an additional 581,475 shares during the last quarter. Institutional investors and hedge funds own 97.79% of the company's stock.

Remove Ads

Halozyme Therapeutics Price Performance

HALO stock traded down $3.12 during trading on Thursday, reaching $57.54. The company's stock had a trading volume of 349,059 shares, compared to its average volume of 1,400,519. The company's fifty day moving average is $60.12 and its 200-day moving average is $54.89. The company has a market capitalization of $7.11 billion, a P/E ratio of 16.76, a price-to-earnings-growth ratio of 0.42 and a beta of 1.32. Halozyme Therapeutics, Inc. has a 1 year low of $37.73 and a 1 year high of $66.00. The company has a quick ratio of 9.15, a current ratio of 7.80 and a debt-to-equity ratio of 4.14.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its quarterly earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.17 by $0.02. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. The company had revenue of $298.01 million for the quarter, compared to the consensus estimate of $285.74 million. On average, research analysts expect that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Insider Transactions at Halozyme Therapeutics

In other news, Director Jeffrey William Henderson sold 503 shares of the company's stock in a transaction on Tuesday, April 1st. The shares were sold at an average price of $64.05, for a total value of $32,217.15. Following the sale, the director now directly owns 33,108 shares of the company's stock, valued at $2,120,567.40. This represents a 1.50 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Michael J. Labarre sold 1,697 shares of Halozyme Therapeutics stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $58.28, for a total value of $98,901.16. Following the transaction, the senior vice president now owns 173,756 shares of the company's stock, valued at $10,126,499.68. The trade was a 0.97 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 22,200 shares of company stock valued at $1,286,568. 2.40% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several equities analysts have recently issued reports on HALO shares. Piper Sandler upped their target price on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a "neutral" rating in a report on Friday, January 10th. HC Wainwright restated a "buy" rating on shares of Halozyme Therapeutics in a research report on Thursday, March 6th. Benchmark reaffirmed a "buy" rating and set a $75.00 target price on shares of Halozyme Therapeutics in a report on Thursday, February 20th. Finally, Wells Fargo & Company lowered their target price on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating on the stock in a research note on Monday, January 13th. Four analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $62.78.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.